Aromatase inhibitors in breast cancer
In advanced disease, aromatase inhibitors as first-line therapy have been shown to extend the time to disease progression (strong scientific evidence). Adjuvant therapy with aromatase inhibitors has been shown to reduce the risk for recurrence after followup of approximately 5 years (strong scientif...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Stockholm
Swedish Council on Health Technology Assessment (SBU)
2005, 2005
|
| Series: | SBU alert report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | In advanced disease, aromatase inhibitors as first-line therapy have been shown to extend the time to disease progression (strong scientific evidence). Adjuvant therapy with aromatase inhibitors has been shown to reduce the risk for recurrence after followup of approximately 5 years (strong scientific evidence). No scientific evidence is yet available on long-term effects concerning survival and side effects (beyond 5 years). Only limited evidence is available on the cost effectiveness of using aromatase inhibitors |
|---|---|
| Physical Description: | 1 PDF file (2 pages) |